Ekbom, K, Ulfberg, J. Restless legs syndrome. J Intern Med. 2009; 266(5): 419–431.
Winkelman, JW, Chertow, GM, Lazarus, JM. Restless legs syndrome in end-stage renal disease. Am J Kidney Dis. 1996; 28(3): 372–378.
Benz, RL, Pressman, MR, Hovick, ET, Peterson, DD. Potential novel predictors of mortality in end-stage renal disease patients with sleep disorders. Am J Kidney Dis. 2000; 35(6): 1052–1060.
Lin, CH, Sy, HN, Chang, HW, et al. Restless legs syndrome is associated with cardio/cerebrovascular events and mortality in end‐stage renal disease. Eur J Neurol. 2015; 22(1): 142–149.
Nichols, DA, Allen, RP, Grauke, JH, et al. Restless legs syndrome symptoms in primary care: a prevalence study. Arch Intern Med. 2003; 163(19): 2323–2329.
Berger, K, Luedemann, J, Trenkwalder, C, John, U, Kessler, C. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med. 2004; 164(2): 196–202.
Al-Jahdali, HH, Al-Qadhi, WA, Khogeer, HA, Al-Hejaili, FF, Al-Ghamdi, SM, Al Sayyari, AA. Restless legs syndrome in patients on dialysis. Saudi J Kidney Dis Transpl. 2009; 20(3): 378–385.
Lee, J, Nicholl, DD, Ahmed, SB, et al. J Clin Sleep Med. 2013; 9(5): 455–459.
Möller, C, Wetter, TC, Köster, J, Stiasny-Kolster, K. Differential diagnosis of unpleasant sensations in the legs: prevalence of restless legs syndrome in a primary care population. Sleep Med. 2010; 11(2): 161–166.
Lohr, JB, Eidt, CA, Alfaraj, AA, Soliman, MA. The clinical challenges of akathisia. CNS Spectr. 2015; 20(S1): 1–16.
Sachdev, P. Akathisia and Restless Legs. New York, USA: Cambridge University Press; 2006.
Allen, RP, Picchietti, DL, Garcia-Borreguero, D, et al. Restless legs syndrome/Willis–Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria—history, rationale, description, and significance. Sleep Med. 2014; 15(8): 860–873.
Pichler, I, Hicks, A, Pramstaller, P. Restless legs syndrome: an update on genetics and future perspectives. Clin Genet. 2008; 73(4): 297–305.
Young, JE, Vilariño-Güell, C, Lin, S-C, Wszolek, ZK, Farrer, MJ. Clinical and genetic description of a family with a high prevalence of autosomal dominant restless legs syndrome. Mayo Clin Proc. 2009; 84(2): 134–138.
Scheller, D, Ullmer, C, Berkels, R, Gwarek, M, Lübbert, H. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. Naunyn Schmiedebergs Arch Pharmacol. 2009; 379(1): 73–86.
Winkelmann, J, Schormair, B, Lichtner, P, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet. 2007; 39(8): 1000–1006.
Kemlink, D, Polo, O, Frauscher, B, et al. Replication of restless legs syndrome loci in three European populations. J Med Genet. 2009; 46(5): 315–318.
Michaud, M, Soucy, J-P, Chabli, A, Lavigne, G, Montplaisir, J. SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. J Neurol. 2002; 249(2): 164–170.
Connor, JR, Wang, X-S, Allen, RP, et al. Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain. 2009; 132(9): 2403–2412.
Siddiqui, S, Kavanagh, D, Traynor, J, Mak, M, Deighan, C, Geddes, C. Risk factors for restless legs syndrome in dialysis patients. Nephron Clin Pract. 2005; 101(3): c155–c160.
Azar, S, Hatefi, R, Talebi, M. Evaluation of effect of renal transplantation in treatment of restless legs syndrome. Transplant Proc. 2007; 39(4): 1132–1133.
Kim, J-M, Kwon, H-M, Lim, CS, Kim, YS, Lee, S-J, Nam, H. Restless legs syndrome in patients on hemodialysis: symptom severity and risk factors. J Clin Neurol. 2008; 4(4): 153–157.
Kawauchi, A, Inoue, Y, Hashimoto, T, et al. Restless legs syndrome in hemodialysis patients: health-related quality of life and laboratory data analysis. Clin Nephrol. 2006; 66(6): 440–446.
Silber, MH, Becker, PM, Earley, C, et al. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc. 2013; 88(9): 977–986.
Lettieri, CJ, Eliasson, AH. Pneumatic compression devices are an effective therapy for restless legs syndrome: a prospective, randomized, double-blinded, sham-controlled trial. Chest. 2009; 135(1): 74–80.
Giannaki, CD, Sakkas, GK, Karatzaferi, C, et al. Effect of exercise training and dopamine agonists in patients with uremic restless legs syndrome: a six-month randomized, partially double-blind, placebo-controlled comparative study. BMC Nephrol. 2013; 14: 194.
Kaye, CM, Nicholls, B. Clinical pharmacokinetics of ropinirole. Clinical Pharmacokinet. 2000; 39(4): 243–254.
Montplaisir, J, Karrasch, J, Haan, J, Volc, D. Ropinirole is effective in the long‐term management of restless legs syndrome: A randomized controlled trial. Mov Disord. 2006; 21(10): 1627–1635.
Pellecchia, MT, Vitale, C, Sabatini, M, et al. Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial versus levodopa sustained release. Clinical Neuropharmacol. 2004; 27(4): 178–181.
Antonini, A, Calandrella, D. Pharmacokinetic evaluation of pramipexole. Expert Opin Drug Metab Toxicol. 2011; 7(10): 1307–1314.
Dauvilliers, Y, Benes, H, Partinen, M, et al. Rotigotine in hemodialysis-associated restless legs syndrome: a randomized controlled trial. Am J Kidney Dis. 2016; 68(3): 434–443.
Williams, A-M, Garcia-Borreguero, D. Management of restless legs syndrome augmentation. Curr Treat Options Neurol. 2009; 11(5): 327–332.
Paulus, W, Trenkwalder, C. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurol. 2006; 5(10): 878–886.
Ferini-Strambi, L. Restless legs syndrome augmentation and pramipexole treatment. Sleep Med. 2002; 3(Suppl): S23–S25.
Winkelman, JW, Johnston, L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med. 2004; 5(1): 9–14.
Quilici, S, Abrams, K, Nicolas, A, et al. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep Med. 2008; 9(7): 715–726.
Miranda, M, Kagi, M, Fabres, L, et al. Pramipexole for the treatment of uremic restless legs in patients undergoing hemodialysis. Neurology. 2004; 62(5): 831–832.
Oertel, W, Beneš, H, Bodenschatz, R, et al. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR). Neurology. 2006; 67(6): 1040–1046.
Nutt, JG, Woodward, WR, Anderson, JL. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann Neurol. 1985; 18(5): 537–543.
Akpinar, L. Restless legs syndrome treatment with dopaminergic drugs. Clin Neuropharmacol. 1987; 10(1): 69–79.
Saletu, M, Anderer, P, Högl, B, et al. Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome. J Neural Transm. 2003; 110(6): 611–626.
Allen, RP, Earley, CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep. 1996; 19(3): 205–213.
Högl, B, García-Borreguero, D, Kohnen, R, et al. Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol. 2010; 257(2): 230–237.
Trenkwalder, C, Stiasny, K, Pollmächer, T, et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep. 1995; 18(8): 681–688.
Walker, SL, Fine, A, Kryger, MH. L-DOPA/carbidopa for nocturnal movement disorders in uremia. Sleep. 1996; 19(3): 214–218.
Bockbrader, HN, Wesche, D, Miller, R, Chapel, S, Janiczek, N, Burger, P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010; 49(10): 661–669.
Happe, S, Sauter, C, Klösch, G, Saletu, B, Zeitlhofer, J. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology. 2003; 48(2): 82–86.
Hassan, HIC, Brennan, F, Collett, G, Josland, EA, Brown, MA. Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. J Pain Symptom Manage. 2015; 49(4): 782–789.
Thorp, ML, Morris, CD, Bagby, SP. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis. 2001; 38(1): 104–108.
Micozkadıoglu, H, Ozdemir, FN, Kut, A, Sezer, S, Saatci, U, Haberal, M. Gabapentin versus levodopa for the treatment of restless legs syndrome in hemodialysis patients: an open‐label study. Ren Fail. 2004; 26(4): 393–397.
Joy, MS. Clonazepam: benzodiazepine therapy for the restless legs syndrome. ANNA J. 1997; 24(6): 686–689.
Saletu, M, Anderer, P, Saletu-Zyhlarz, G, et al. Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): acute placebo-controlled sleep laboratory studies with clonazepam. Eur Neuropsychopharmacol. 2001; 11(2): 153–161.
Read, D, Feest, T, Nassim, M. Clonazepam: effective treatment for restless legs syndrome in uraemia. Br Med J (Clin Res Ed). 1981; 283(6296): 885–886.
Von Spiczak, S, Whone, AL, Hammers, A, et al. The role of opioids in restless legs syndrome: an [11C] diprenorphine PET study. Brain. 2005; 128(4): 906–917.
Kaplan, PW, Allen, RP, Buchholz, DW, Walters, JK. A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep. 1993; 16(8): 717–723.
Walters, AS, Winkelmann, J, Trenkwalder, C, et al. Long‐term follow‐up on restless legs syndrome patients treated with opioids. Mov Disord. 2001; 16(6): 1105–1109.
Earley, CJ, Heckler, D, Allen, RP. Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome. Sleep Med. 2005; 6(4): 301–305.
Grote, L, Leissner, L, Hedner, J, Ulfberg, J. A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov Disord. 2009; 24(10): 1445–1452.
Giannaki, CD, Hadjigeorgiou, GM, Karatzaferi, C, Pantzaris, MC, Stefanidis, I, Sakkas, GK. Epidemiology, impact, and treatment options of restless legs syndrome in end-stage renal disease patients: an evidence-based review. Kidney Int. 2014; 85(6): 1275–1282.
Winkelmann, J, Stautner, A, Samtleben, W, Trenkwalder, C. Long‐term course of restless legs syndrome in dialysis patients after kidney transplantation. Mov Disord. 2002; 17(5): 1072–1076.